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Abstract
Introduction: Patients with chronic inflammatory diseases have increased bone loss and bone fragility and are at
increased risk of fracture. Although anti-resorptive drugs are effective in blocking inflammation-induced bone loss,
they are less effective at rebuilding bone. We have previously shown that treatment with sclerostin antibody
(Scl-AbI) builds bone and can prevent or restore bone loss in a murine model of inflammatory bowel disease. In
this study, we tested the effect of Scl-AbI in a murine model of rheumatoid arthritis (the collagen-induced arthritis
model, CIA). We hypothesised that sclerostin blockade can protect and restore bone both locally and systemically
without affecting progression of inflammation.
Methods: CIA was induced in male DBA/1 mice, which were treated with either PBS or Scl-AbI (10 mg/kg, weekly)
prophylactically for 55 days or therapeutically for 21 days (starting 14 days post onset of arthritis). Systemic
inflammation was assessed by measuring the serum concentration of anti-CII IgG1, IgG2a and IgG2b by ELISA.
Changes in bone mass and structure, either at sites remote from the joints or at periarticular sites, were measured
using DEXA and microCT. Bone focal erosion was assessed in microCT scans of ankle and knee joints.
Results: Circulating anti-CII immunoglobulins were significantly elevated in mice with CIA and there were no
significant differences in the levels of anti-CII immunoglobulins in mice treated with PBS or Scl-ABI. Prophylactic
Scl-AbI treatment prevented the decrease in whole body bone mineral density (BMD) and in the bone volume
fraction at axial (vertebral body) and appendicular (tibial proximal metaphysis trabecular and mid-diaphysis cortical
bone) sites seen in PBS-treated CIA mice, but did not prevent the formation of focal bone erosions on the
periarticular bone in the knee and ankle joints. In the therapeutic study, Scl-AbI restored BMD and bone volume
fraction at all assessed sites but was unable to repair focal erosions.
Conclusions: Sclerostin blockade prevented or reversed the decrease in axial and appendicular bone mass in the
murine model of rheumatoid arthritis, but did not affect systemic inflammation and was unable to prevent or
repair local focal erosion.
Keywords: Sclerostin, sclerostin antibody, inflammation, collagen-induced arthritis, rheumatoid arthritis, bone loss,
focal erosion, micro computed tomography, microCT
Introduction
Patients with chronic inflammatory diseases - for example
rheumatoid arthritis (RA), systemic lupus erythematosus,
inflammatory bowel disease (IBD), celiac disease, cystic
fibrosis and chronic obstructive pulmonary disease - have
increased bone fragility and are at an increased risk of
sustaining a bone fracture [1]. Possible reasons for the
increased fracture risk include: poor nutritional status,
hypovitaminosis D, a decrease in calcium intake, corticos-
teroids treatment, reduced mobility and exercise, and
systemic chronic inflammation. Chronic inflammation
is believed to be one of the key factors and is active from
the early stages of all of the aforementioned inflammatory
diseases [2]. Inflammatory bone loss is regulated by
various mediators of the immune system such as the
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pro-inflammatory cytokines tumour necrosis factor-alpha
(TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6
(IL-6), or interferon-gamma, which have all been shown to
modulate osteoclastogenesis [1]. Other cytokines such as
receptor activator of nuclear factor kappa B (RANK), its
ligand, RANKL, and osteoprotegerin (OPG) are also criti-
cally involved in the pathophysiology of inflammatory
bone loss [3]. Moreover, inflammatory factors such as
TNF-alpha have also been shown to reduce osteoblast
activity, thereby inhibiting the formation of new bone.
Although anti-resorptive approaches, such as bisphospho-
nates, denosumab, IL-1 receptor antagonist, and TNF-
alpha antibody have been effective in slowing or blocking
inflammation-induced bone loss, they have shown a
limited capacity to restore lost bone [2].
RA is an autoimmune disease with both articular and
extra-articular involvement. The main consequence of
RA is the induction of structural joint damage, a source of
physical and social handicap leading to a huge economic
cost. Thus, new treatments to stop RA evolution are an
important need for both patients and society. In early RA,
radiographic demineralisation appears around inflamed
joints, while bone erosions appear later [4].
Several Wnt family members seem to be involved in
the modulation of the inflammatory response during RA
[5-7]. Wnt-7b was shown to be upregulated in the carti-
lage of osteoarthritic patients and in the synovium of
RA patients, where it has been implicated in the produc-
tion of the pro-inflammatory cytokines TNF-alpha and
IL-1-beta [8]. Additional data supporting a role of the
Wnt signalling pathway in the pathogenesis of RA
comes from the fact that the blockade of Wnt-5a/
Frizzled5 signalling decreases IL-6 and IL-15 production
during the activation of fibroblast-like synoviocytes
(FLSs) [9]. Moreover, Wnt-1 was shown to regulate
fibronectin and promote matrix metalloproteinase-3
(MMP-3) production in FLSs [10] and Wnt-1-inducible
signalling pathway protein-2 (WISP2) was shown to be
upregulated in RA synovial fibroblasts [11]. Therefore,
as well as direct effects on bone formation, Wnt family
members might also have an indirect impact on bone
metabolism by modulating inflammatory responses.
Inflammation can also affect the regulation of Wnt sig-
naling [5]. The induction of Dickkopf-1 (DKK1) by
TNF-alpha and the consequent inhibition of the Wnt
signalling pathway have been observed both in human
RA [12,13] and in murine arthritis models [14]. In this
case, TNF-alpha-mediated DKK1 regulation represents a
major factor in the blockade of osteoblast development,
resulting in the inflamed joint going unrepaired [15].
Therapeutic scavenging of DKK1 by inhibitory antibo-
dies in the human TNF transgenic mouse model
resulted in an increase in bone formation, leading to the
maintenance of joint integrity as well as the local
development of osteophytes: bony spurs that are charac-
teristic of degenerative joint remodelling processes [16].
Sclerostin blockade with a monoclonal antibody (Scl-AbI)
has been shown to stimulate bone formation in both
humans and animal models [17]. We have recently
shown that systemic bone loss in a mouse model of IBD
was prevented and reversed with a blocking antibody to
sclerostin [18]. This caused reactivation of Wnt signalling
in osteoblasts, which was reflected in a reduction of the
circulating osteoclastic marker (tartrate-resistant acid
phosphatase, TRAP) and an increase of the osteoblastic
marker (osteocalcin).
Given the prominent role of Wnt signaling in RA, we
hypothesised that sclerostin blockade may exert a bone-
protective or restoring action, both locally and systemi-
cally, without affecting progression of inflammation
(consistent with our previous study). To test this
hypothesis, we have used a murine model of rheumatoid
arthritis, the type II collagen-induced arthritis (CIA)
model. This model is known to induce both systemic
osteopenia and periarticular bone loss leading to loss of
joint integrity, as seen in RA in patients [16,17]. We
treated CIA mice with Scl-AbI and focused our analysis
on the changes in bone mass and structure either at
sites remote from the joints and at periarticular sites
using dual-energy X-ray absorptiometry (DEXA) and
micro computed tomography (microCT).
Methods
Mice
Eight- to ten-week-old male DBA/1 mice were purchased
from Harlan Laboratories (Bicester, UK). Mice were
housed in cages in an environmentally controlled room
(temperature 21°C to 23°C and relative humidity 38%
to 50%) on a 12-hour light/dark cycle according to
UK Home Office regulations. Animals had access to
RM1 food pellets (Lillico, Betchworth, UK) and water
ad libitum. Animals were acclimatised for four weeks
before use.
The work was conducted in the UK according to the
Animals Scientific Procedures Act (1986) and was covered
by a Project Licence that was subject to both ethical
review by AURICC (Animal Use in Research Coordinating
Committee) and Government review (UK Home Office).
Induction/assessment of collagen-induced arthritis and
bone mineral density
Collagen-induced arthritis (CIA) was induced as
described earlier [21]. In brief, cages of male DBA/1
mice (n = 5 per cage) were weighed and placed into
groups (n = 15 per group) to give similar initial body
weights. Chicken type II collagen (CII) (MD Biosciences,
Zurich, Switzerland) was dissolved in 0.1 M acetic acid
at 2 mg/mL and constantly rolled overnight in the dark
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at 4°C. The next day (Day 0) the CII solution was emul-
sified in an equal volume of complete Freund’s adjuvant
(CFA, Sigma-Aldrich, Gillingham, UK) to give a 1 mg/mL
emulsion. DBA/1 mice were injected with 0.1 mL (100 μg
CII) of emulsion into the base of the tail by an intradermal
route under anaesthesia. Fourteen days post-sensitisation
mice were given a booster injection of CII, by intradermal
route as above, but with incomplete Freund’s adjuvant
(Sigma-Aldrich), instead of CFA. Mice were assessed for
signs of arthritis from day 14 onwards. When signs of
arthritis were seen, mice were weighed and clinically
scored. Clinical score was graded on a 0 to 3 scale as
follows: grade 0, no swelling; grade 1, wrist or ankle
swollen; grade 2, wrist/ankle and pad swollen; grade 3,
wrist/ankle, pad and digits swollen. Clinical score was the
sum of all four paws (maximum score per mouse was 12).
Study design
In the prophylactic study, arthritis was induced in two
groups of male DBA/1 mice (n = 15/group). Starting
from one day prior to collagen II sensitisation, one
group of mice was treated with 10 mg/kg (100 μL subcuta-
neously once per week) of a monoclonal antibody directed
against sclerostin [18-22] and the other with PBS (100 μL
subcutaneously once a week). A third group of mice
(n = 6) was used as age-matched, healthy, untreated
controls. The prophylactic study was terminated 55 days
post-sensitisation.
In the therapeutic study, arthritis was induced in three
groups of male DBA/1 mice. For each animal, onset of
arthritis was considered to be day 1. One group of mice
was treated with 10 mg/kg of Scl-AbI (n = 11) and a
second group with PBS (100 μl subcutaneously once a
week) (n = 14) starting from 14 days post-onset of
arthritis. These groups were terminated 21 days after
starting treatment. Arthritis was induced in a third
group of mice, with each animal killed 14 days after
onset of arthritis (n = 7) to act as a baseline for treat-
ment comparisons. A fourth group of mice (n = 4) was
used as age-matched, healthy, untreated controls.
Bone assessment and analysis
At termination of the studies, mice were killed and total
(excluding the skull) and vertebral bone mineral density
(BMD) were assessed using dual-energy X-ray absorptio-
metry (DEXA, Lunar PIXImus, GE Medical Systems, Little
Chalfont, UK). Dissected hind limbs (from the hip joint
to the ankle) and L5 lumbar vertebrae were scanned
by microCT (SCANCO, Brüttisellen, Switzerland, μCT35)
at 70 kVp and 160 μA, with resolution of 6 μm isotropic
voxel size. Segmentation, selection of regions of interest
and computation of three-dimensional microstructural
parameters were performed by SCANCO proprietary soft-
ware (image processing language, IPL), as previously
reported [23]. Noise was removed from images using a
Gaussian filter (sigma = 0.8 and support = 1) and fixed
threshold of 500 mg/cm3 was used to segment bone from
the background. Analysis of the tibia was performed in
two regions: 1) the mid-diaphysis cortical bone, a 0.6 mm-
long segment (or 100 tomograms) centred over the tibial
midline, and 2) the proximal tibial metaphysis, a region
starting 0.30 mm from an anatomic landmark in the
growth plate and extending 1.2 mm (or 200 tomograms)
distally. The vertebral bodies of L5 vertebra, including
upper and lower discs, were selected from the scout view
images of the whole mouse spine. Regions of interest were
manually drawn to include trabecular bone and exclude
cortical bone in either the tibial metaphysis or the L5
vertebral body. To evaluate bone focal erosion in the ankle
joint and knee joint, these anatomical regions were
selected by manually drawn regions of interest (640 tomo-
grams centered over the synovial space for the knee joint
and 700 tomograms including all the bones in the tarsus
and the calcaneus). Bone volume (BV) and bone surfaces
(BS) of these entire articular joints were then computed.
To evaluate the surface density of the periarticular bone
(indicating focal erosion on the bone surfaces) the ratio
BS/BV was used similarly as previously reported [23].
However, since BS/BV depends on bone volume changes,
another independent parameter was introduced to
estimate the smoothness of the periarticular bone surfaces.
This was obtained by first recalculating the parameter
BS - which was re-named BSsmooth - after applying a
strong smoothing filter (Gaussian with sigma = 2.5 and
support = 5) to the microCT images. Then the ratio of
BSsmooth over the original BS was computed as estimator
of surface smoothness. This estimator has a value close to
one for perfectly smooth surfaces where additional
smoothing does not cause changes in the parameter BS,
and close to zero for extremely rough surfaces where
strong smoothing dramatically alters the value of BS.
Serological analysis of immunoglobulins
The presence of anti-CII immunoglobulins (IgG1, IgG2a
and IgG2b) was determined by ELISA in serum samples
obtained at termination of the prophylactic study
(Day 55). In brief, 96-well ELISA plates were coated
with 5 μg/mL CII (MD Biosciences) dissolved in PBS
(100 μL per well). Plates were covered and stored over-
night at 4°C. The next day plates were washed twice
with PBS on an automated plate washer then blocked
with 1% bovine serum albumin (BSA) in PBS (200 μL
per well) and placed on a plate shaker for 30 minutes at
room temperature. Plates were then washed twice with
PBS. Serum samples were diluted in PBS at 1 in 10,000
for detection of anti-CII IgG1 and IgG2a and 1 in
20,000 for detection of anti-CII IgG2b, 100 μL of each
sample were plated out in duplicate. Plates were placed
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on a plate shaker for 1 hour at room temperature and
then washed twice with PBS. Anti-mouse IgG1, IgG2a
and IgG2b horseradish peroxidase-conjugated antibodies
(AbD Serotec, Kidlington, UK) were diluted from stock
1 in 5,000 in PBS containing 1% BSA and 100 μL per
well added to plates. Plates were then placed on a plate
shaker for 1 hour at room temperature and then washed
four times with PBS. 3, 3’, 5, 5’ tetramethylbenzidine
substrate (Sigma-Aldrich) was added to the plates
(100 μL per well). The reaction was stopped after 10
minutes with 100 μL 1N sulphuric acid. Transmitted
light absorbance was read on a plate reader at 450 nm
wavelength.
Statistics
Data were analysed using GraphPad Prism v.5.0. (Graph-
Pad Software, La Jolla, CA, USA) Data are represented
as means +/- standard deviations with the exception of
the clinical scores and serological results, which are
represented as means +/- standard error of the mean.
Statistical analysis of all data, except for the clinical
scores, was conducted by one-way ANOVA with Tukey’s
post hoc test. Differences between clinical score were
analysed by Mann-Whitney test. Values of P < 0.05 were
considered statistically significant.
Results
Prophylactic study - treatment with Scl-AbI has no
significant effect on clinical scores and systemic
inflammation in CIA mice
Mice receiving Scl-AbI had an incidence of disease that
was not significantly different from mice treated with
PBS (Figure 1A). Furthermore, the mean clinical score
did not significantly differ in the two groups throughout
the course of the experiment (Figure 1B). There was little
change in body weight of the mice (approximately 23 g)
during the course of the experiment in either the
presence or absence of Scl-AbI treatment. Serum samples
taken at the end of the study were analysed by ELISA
for the presence of circulating anti-CII antibodies.
Figure 1 Prophylactic administration of sclerostin antibody to CIA mice has no effect on clinical scores and systemic inflammation.
Two groups of male DBA/1 mice were sensitized to collagen type II to induce arthritis. One group were treated with vehicle (collagen-induced
arthritis (CIA) + PBS; n = 15) and the other group received 10 mg/kg sclerostin antibody (Scl-AbI) (CIA + Scl-AbI; n = 15). PBS or Scl-AbI were
injected subcutaneously once weekly until termination of the experiment (day 55). (A) Incidence (reported as percentage of animals involved)
and (B) clinical score of arthritis were assessed daily and are displayed as mean ± SEM. (C, D, E) Bar plots ± SEM represent serum concentrations
of anti-CII immunoglobulins IgG1, IgG2a and IgG2b respectively in each group. Serum from age-matched healthy control mice (CTR; n = 6) were
analysed for baseline levels of anti-CII antibodies. Differences between clinical scores were analysed by Mann-Whitney test. The one-way ANOVA
test with Tukey’s post hoc comparison was used for statistical evaluation of the serum concentration results shown in the bar plots. *P < 0.05 for
the difference versus CTR.
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Scl-AbI treatment had no significant effect on the
concentration of anti-CII immunoglobulins (IgG1, IgG2a
or IgG2b), which were all significantly elevated in PBS-
treated arthritic mice compared with healthy controls
(Figure 1C, D, E).
Prophylactic study - treatment with Scl-AbI prevented
whole body BMD, axial and tibial bone losses in CIA mice
Mice sensitised to CII, and treated with PBS, showed a
statistically significant decrease in the bone volume
fraction (BV/TV) in L5 vertebral body (Figure 2A, B)
compared with healthy controls, which was primarily
due to thinning of the trabeculae (Figure 2C). Prophy-
lactic treatment of the sensitised mice with Scl-AbI pre-
vented these changes and increased both BV/TV and
trabecular thickness above untreated healthy controls.
Interestingly, similar results were found for the trabe-
cular bone in the tibial metaphysis (Figure 2D, E),
despite the relative proximity to the knee joint, which is
an area focally targeted in the disease model. The mid-
diaphysis cortical bone thickness in the tibia was also
reduced in sensitised mice treated with PBS compared to
healthy untreated mice, although this trend did not reach
statistical significance. Scl-AbI treatment significantly
Figure 2 Prophylactic administration of sclerostin antibody to CIA mice prevents systemic bone loss. (A, D) Representative three-
dimensional renditions of the trabecular bone within the L5 vertebral body and the tibial metaphysis, respectively, scanned by micro computed
tomography. (B, C) Bar plots represent mean (and standard deviation) of the trabecular bone volume fraction (BV/TV) in the vertebral body and
the trabecular thickness (Tb.Th). (E, F) Bar plots represent mean (and standard deviation) of the trabecular bone volume fraction (BV/TV), the
tibial metaphysis and the cortical thickness of the cortical bone in the tibia midshaft. (G) Bar plot represents mean (and standard deviation) of
the bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DEXA). The groups treated with PBS or sclerostin antibody
(Scl-AbI) were split into diseased (PBS n = 11, Scl-AbI n = 11) and non-diseased mice (PBS n = 4, Scl-AbI n = 4). A group of age-matched healthy
controls (CTR n = 6) were used to determine baseline bone mineral density (BMD). The one-way ANOVA test with Tukey’s post hoc comparison
was used for statistical evaluation of all parameters shown in the bar plots. *P < 0.05 for the difference versus CTR; #P < 0.05 for the difference
versus collagen-induced arthritis (CIA) + PBS (and diseased/non-diseased PBS in graph G).
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increased tibial cortical thickness compared to both PBS-
treated and healthy untreated mice (Figure 2F). This
increase in cortical thickness appeared to be due primarily
to endosteal bone apposition since the diaphysis total
volume (cortical bone volume plus marrow volume) was
unchanged between PBS- and Scl-AbI-treated mice, while
the marrow volume was significantly decreased (1.6-fold,
data not shown).
Mice sensitised to CII showed a statistically significant
decrease in whole body BMD as compared to age-matched
control mice 55 days post-sensitisation (Figure 2G).
Scl-AbI treatment completely prevented this BMD loss in
CIA mice and further increased their mean BMD above
healthy control level by the end of the experiment (Figure
2G). Whole body BMD within the subpopulations of
CII-sensitised mice with either active arthritis (diseased)
or those with no signs of arthritis (non-diseased) were
assessed. Non-diseased mice had similar total BMD to
those of age-matched healthy control mice. However,
mice with active disease showed a statistically significant
decrease in BMD as compared to non-diseased mice
suggesting an association between active inflammation of
the paws and loss of whole body BMD (Figure 2G).
Treatment with Scl-AbI also caused a statistically signi-
ficant increase in total BMD in both diseased and non-
diseased mice as compared to PBS-treated diseased and
PBS-treated non-diseased mice respectively (Figure 2G).
Prophylactic study - treatment with Scl-AbI does not
protect from focal bone loss in CIA mice
The effect of focal bone erosion on bone microstructure
was assessed by microCT imaging of either ankle joint
or knee joint. The periarticular bone in the ankles of the
mice sensitised to CII showed a statistically significant
decrease in the parameter evaluating surface smoothness
(BSsmooth/BS, Figure 3A) and increase in the parameter
quantifying surface density (BS/BV, Figure 3B) compared
to age-matched control mice 55 days post-sensitisation.
Treatment with Scl-AbI was able to prevent the changes
in the BS/BV but not in the BSsmooth/BS. This effect
Figure 3 Prophylactic administration of sclerostin antibody to CIA mice does not prevent focal bone erosion in periarticular bone in
the ankle joint. (A, B, C) Bar plots represent mean (and standard deviation of) smoothness parameter (BSsmooth/BS), ratio between bone
surface and bone volume (BS/BV), representing surface density, and ankle joint bone volume (BV), respectively. (D) Representative three-
dimensional renditions of the hind paws scanned by micro computed tomography. (E) Representative longitudinal mid-sections on the ankle
joint and all the bones in the tarsus. Bone volume and erosion parameters were evaluated in the region of interest displayed on the panel A
(dotted selection on control (CTR)). The one-way ANOVA test with Tukey’s post hoc comparison was used for statistical evaluation of all
parameters shown in the bar plots. *P < 0.05 for the difference versus CTR; #P < 0.05 for the difference versus collagen-induced arthritis (CIA) + PBS.
Marenzana et al. Arthritis Research & Therapy 2013, 15:R125
http://arthritis-research.com/content/15/5/R125
Page 6 of 12
appeared to be due to an antibody-mediated significant
increase in bone volume (Figure 3C), rather than a reduc-
tion of the superficial pitting (Figure 3A). This was
clearly visualised in the three-dimensional renditions,
showing the superficial pitting (Figure 3D) in both the
Scl-AbI- and PBS-treated diseased mice. The two-dimen-
sional longitudinal virtual sections of the ankle joint
show that bone volume increased internally from the
endosteal surfaces (Figure 3E).
Similar results were found in the periarticular bone
in the knee joints where the BS/BV was increased com-
pared to age-matched control mice, although the differ-
ence did not reach statistical significance (Figure 4A).
This increase was not observed in the Scl-AbI-treated
group and again this appeared to be due to an increase
in bone volume (Figure 4B) from the endosteal surfaces.
Qualitative analysis of the three-dimensional renditions
of the knee joints (Figure 4C) confirmed that Scl-AbI
treatment had been unable to prevent the external focal
erosion on the periarticular surfaces.
Therapeutic study - treatment with Scl-AbI has no effect
on clinical scores
Fifteen mice per group were sensitised to CII. Out of
these, 14 mice developed disease in the PBS assigned
group and 11 developed disease in the Scl-AbI assigned
group, which indicates a robust disease induction before
dosing was initiated. PBS and Scl-AbI were only admi-
nistered to mice with active disease. Scl-AbI-treatment
from 14 days post disease onset had no statistically sig-
nificant effect on the mean clinical score throughout the
course of the therapeutic study (Figure 5). As in the
prophylactic dosing study, the body weight of the mice
(approximately 23 g) in both the control and SclAbI-
dosed groups varied little during the course of the
experiment.
Figure 4 Prophylactic administration of sclerostin antibody to CIA mice does not prevent focal bone erosion in periarticular bone in
the knee joint. (A, B) Bar plots represent mean (and standard deviation of) ratio between bone surface and bone volume (BS/BV), representing
surface density, and ankle joint bone volume (BV), respectively. (C) Representative three-dimensional renditions of the knee joint scanned by
micro computed tomography. The one-way ANOVA test with Tukey’s post hoc comparison was used for statistical evaluation of all parameters
shown in the bar plots. #P < 0.05 for the difference versus collagen-induced arthritis (CIA) + PBS.
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Therapeutic study - treatment with Scl-AbI fully reverses
whole body BMD, axial and tibial trabecular bone losses
in CIA mice
Mice scanned 14 days after the onset of arthritis con-
firmed that whole body BMD loss was already established
at the start of the treatment and also revealed that disease
progression did not further decrease BMD (Figure 6A).
Arthritic mice treated with PBS showed a statistically
significant decrease in whole body BMD as compared to
age-matched control mice 35 days post disease onset
(Figure 6A). Treatment with Scl-AbI restored whole body
BMD to the same level as the healthy untreated control
mice (Figure 6A, E).
Arthritic mice treated with PBS showed a statistically
significant decrease in the bone volume fraction (BV/TV)
in L5 vertebral body (Figure 6B), which was primarily
due to thinning of the trabeculae (Figure 6C), consistent
with findings in the prophylactic study. Therapeutic
treatment of the arthritic mice with Scl-AbI significantly
increased BV/TV and trabecular thickness compared
with PBS treated and with BV/TV even significantly
higher than in untreated healthy controls (Figure 6B). As
in the prophylactic study, the trabecular BV/TV at the
tibial metaphysis was significantly decreased by CIA but
recovered by Scl-AbI treatment to the same level as the
untreated healthy controls (Figure 6D). The mid-diaphyseal
cortical bone thickness was also significantly reduced in
arthritic mice treated with PBS compared to healthy
untreated mice. Arthritic mice treated with Scl-AbI
achieved an average tibial cortical thickness similar to the
healthy untreated mice (Figure 6E).
Therapeutic study - treatment with Scl-AbI does not
repair focal bone erosions in CIA mice
The periarticular bone in the ankle joints of arthritic
mice showed a statistically significant decrease in the
parameter evaluating surface smoothness (BSsmooth/BS,
Figure 7A) and increase in the parameter quantifying
surface density (BS/BV, Figure 7B) compared to age-
matched control mice. Treatment of arthritic mice with
Scl-AbI was able to abrogate the increase in the BS/BV
(not statistically different from healthy untreated controls)
but not the decrease in BSsmooth/BS. This effect appeared
to be due to a significant increase in bone volume (Figure
7C), rather than a reduction of the superficial pitting as
for the prophylactic study. This was confirmed by the
qualitative analysis of three-dimensional renditions of
the ankle joints of the CIA mice of the therapeutic study
(data not shown as very similar to the images shown for
the prophylactic study).
Discussion
In this study, we showed that an antibody to sclerostin
(Scl-AbI) can prevent or restore inflammation-induced
systemic bone loss in a murine model of rheumatoid
arthritis and had no significant effect on inflammation
Figure 5 Therapeutic administration of sclerostin antibody to arthritic mice has no effect on clinical scores. Two groups of male DBA/1
mice were sensitised to collagen type II to induce arthritis. Starting from 14 days post onset of arthritis (that is the disease progression was
synchronised in all mice before starting the treatment) mice were treated subcutaneously once a week with either vehicle (collagen-induced
arthritis (CIA) + PBS; n = 14) or 10 mg/kg sclerostin antibody (Scl-AbI) (CIA + Scl-AbI; n = 11). The therapeutic study was terminated 21 days after
starting treatment. Clinical score of arthritis was evaluated daily and expressed as the mean ± standard error of the mean in each group.
Differences between clinical score were analysed by Mann-Whitney test.
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as assessed by the clinical score (paw inflammation,
Figure 1B and Figure 5A) or on the disease incidence
(in the prophylactic study, Figure 1A). The systemic
decrease in BMD seen in patients with RA is well estab-
lished in epidemiologic studies and can increase fracture
risk especially in the vertebrae [24]. The effects of RA
on systemic bone loss in patients were replicated in our
murine model as shown by a decrease in whole body
BMD (Figure 2G). Indeed by subdividing the sensitised
mice into diseased and non-diseased (Figure 2G), we
have shown that systemic bone loss depends on the
onset of the local inflammation in the appendicular
Figure 6 Therapeutic administration of sclerostin antibody to arthritic mice reverses systemic bone loss. (A) Bar plot represents mean
(and standard deviation of) bone mineral density (BMD) assessed by dual X-ray absorptiometry (DEXA) in vehicle (collagen-induced arthritis (CIA)
+ PBS; n = 14) or sclerostin antibody (Scl-AbI) (CIA + Scl-AbI; n = 11) treated mice. An additional group of untreated diseased mice (n = 7) were
scanned 14 days after onset of arthritis. These mice were used to represent baseline BMD at initiation of therapeutic dosing. BMD in
age-matched healthy control mice (CTR; n = 4) was also assessed. (B, C) Bar plots represent mean (and standard deviation of) trabecular bone
volume fraction (BV/TV) in the L5 vertebral body and trabecular thickness (Tb.Th). (D, E) Bar plots represent mean (and standard deviation of)
trabecular bone volume fraction (BV/TV) the tibial metaphysis and cortical thickness of the cortical bone in the tibia midshaft. The one-way
ANOVA test with Tukey’s post hoc comparison was used for statistical evaluation of all parameters shown in the bar plots. *P < 0.05 for the
difference versus control (CTR); #P < 0.05 for the difference versus CIA + PBS.
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joints. Several studies have shown that strategies aimed
at reducing inflammation (such as TNF-alpha blockade)
are effective in reducing bone loss but not in rebuilding
lost bone [24]. Treatment with Scl-AbI not only pre-
served whole body BMD in diseased animals but also
increased it to levels above that in healthy control mice
(Figure 2G). The same trend was found in a microCT
analysis of the L5 vertebra (Figure 2A, B, C). Surpris-
ingly, the trabecular bone in the tibial metaphysis
followed the same trend, despite its proximity to the
areas of focal erosion (Figure 2D, E, F). Treatment with
Scl-AbI was also effective in restoring whole body BMD
and microstructural parameters in the therapeutic study
(Figure 6).
In our previous study on chronic inflammatory bone
loss in a mouse IBD model [18], we found that the
increase in whole body BMD, and bone microstructural
parameters induced by Scl-AbI treatment, was asso-
ciated with a reduction of inflammation-increased
TRAPC5b and a restoration of inflammation-depressed
osteocalcin serum levels, which corresponds to increasing
bone formation and decreasing bone resorption. It seems
likely that similar mechanisms operated to maintain/
restore whole body BMD in arthritic animals treated with
Scl-AbI. However, in the arthritis model, these mechan-
isms were not effective at modulating focal erosion in the
periarticular bone of the joints affected by the disease.
This was clearly demonstrated using two independent
structural parameters for assessing bone focal erosion,
namely BS/BV (which depends on changes in the bone
volume) and BSsmooth/BS (independent of changes in
bone volume). These parameters revealed that the block-
ade of sclerostin mainly stimulated bone mass accrual on
the endosteal surface but not on the periosteal surface of
the arthritic periarticular bone (Figure 3, Figure 4 and
Figure 7). It is not clear why Scl-AbI is unable to prevent
focal bone loss but it is possible that the intensity or
nature of the inflammatory insult in the immediate
vicinity of the joint may be different from the insult at
more distant sites. The ability of Scl-AbI to mediate
endosteal but not periosteal bone formation in the
inflamed joints might also be attributed to a change in
the inflammatory insult at the two sites. Diarra and
co-investigators reported that an antibody to DKK-1
prevented focal bone loss in a different mouse model of
RA. Dkk-1 and Scl are both regulators of the Wnt signal-
ling pathway (although there seem to be differences in
the members of the Wnt pathway that they inhibit) [16].
However, it is difficult to assess if the transgenic TNF
model used by Diarra et al. generates the same local
inflammatory environment as that observed in the CIA
model reported here. Interestingly, another difference has
been reported between Scl-AbI blockade and blockade of
DKK-1. Whilst DKK-1 blockade appeared to promote
the formation of osteophytes [17], sclerostin blockade
was not associated with osteophyte formation [25]. Inter-
estingly, a recent parallel publication [25], has shown that
that Scl-AbI was able to also protect periarticular bone
erosion in the same transgenic TNF model of RA used by
Diarra and colleagues. This suggests that either the
two models (CIA versus TNF transgenic) lead to very
different degrees of joint inflammation or that other
inflammatory cytokines, besides TNF-alpha, are present
in the arthritic joints of our CIA model.
Further immune-localisation studies are required to
assess the distribution of sclerostin in respect to key
inflammatory cytokines (for example TNF-alpha, IL-1,
IL-6, IL-17 and so on) along the periosteal and endo-
steal surfaces of the arthritic periarticular bone before
firm conclusions can be drawn about the function of
sclerostin in focal erosion areas.
In agreement with our previous study on IBD-induced
bone loss [18], Scl-AbI had no effect on systemic inflam-
mation, measured by circulating IgGs (Figure 1C, D, E).
Figure 7 Therapeutic administration of sclerostin antibody to arthritic mice does not repair focal bone erosion in periarticular bone in
the ankle joint. (A, B, C) Bar plots represent mean (and standard deviation of) smoothness parameter (BSsmooth/BS), ratio between bone
surface and bone volume (BS/BV), representing surface density, and ankle joint bone volume (BV), respectively. CTR, age-matched healthy
controls (n = 4). The one-way ANOVA test with Tukey’s post hoc comparison was used for statistical evaluation of all parameters shown in the
bar plots. *P < 0.05 for the difference versus control (CTR); #P < 0.05 for the difference versus collagen-induced arthritis (CIA) + PBS.
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This is consistent with other studies where bone-specific
treatments have failed to modulate immune reactions
[15,26-29].
Conclusions
In a murine model of rheumatoid arthritis, treatment for
21 days with an antibody to sclerostin reversed a decline
in several axial and appendicular bone microstructural
properties associated with chronic inflammation. How-
ever, treatment with Scl-AbI did not affect markers of
disease severity or prevent/reverse the development of
focal bone erosions in the proximity of inflamed joints.
Thus treatment with an antibody to sclerostin may be
useful in reducing fracture risk in patients suffering
from long-term systemic inflammatory disease but used
alone it may not prevent local joint destruction.
Abbreviations
BMD: bone mineral density; BS: bone surface; BSA: bovine serum albumin;
BSsmooth: computationally smoothed bone surfaces; BV: bone volume; CFA:
complete Freund’s adjuvant; CIA: collagen-induced arthritis; CII: chicken type
II collagen; DEXA: dual-energy X-ray absorptiometry; DKK-1 and DKK-2:
Dickkopf-1 and -2; ELISA: enzyme-linked immunosorbent assay; FLSs:
fibroblast-like synoviocytes; IBD: inflammatory bowel disease; IL-1b, IL-6 and
IL-15: interleukin-1beta, -6 and -15; MMP-3: matrix metalloproteinase-3;
microCT: micro computed tomography; OPG: osteoprotegerin; PBS:
phosphate-buffered saline; RA: rheumatoid arthritis; RANKL: nuclear factor-
kappaB ligand; Scl: sclerostin; Scl-AbI: sclerostin antibody; sFRP1 and sFRP2:
soluble frizzled receptor protein -1 and -2; TNF-alpha: tumor necrosis factor
alpha; Wnt-1, Wnt-7b, Wnt10b and Wnt-5a: wingless-type MMTV (mouse
mammary tumour virus) integration site family, member 1, 7b, 10b and 5a.
Competing interests
AV, AM and MR are employed by UCB Pharma. MM was a former employee
at UCB Pharma and is currently in a joint academic position 50% Imperial
College London and 50% Oxford University. MR owns stock options in UCB
Pharma.
Authors’ contributions
MM and AV are responsible for study design, data acquisition and analysis,
and drafting and revising the manuscript. AM and MR are responsible for
study design, data analysis and interpretation, and revision and final
approval of the manuscript. All authors have read and approved the
manuscript for publication.
Acknowledgements
The authors would like to acknowledge the support of the UCB and Amgen
sclerostin project teams. MM was partially supported by grant number 19844
from Arthritis Research UK.
Authors’ details
1UCB Pharma, 208 Bath Road, Slough, Berkshire, SL1 3WE, UK. 2Department
of Bioengineering, Imperial College London, South Kensington Campus,
London SW7 2AZ, UK.
Received: 8 April 2013 Revised: 20 June 2013
Accepted: 18 September 2013 Published: 18 September 2013
References
1. Redlich K, Smolen JS: Inflammatory bone loss: pathogenesis and
therapeutic intervention. Nat Rev Drug Discov 2012, 11:234-250.
2. Sinigaglia L, Varenna M, Girasole G, Bianchi G: Epidemiology of
osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006,
32:631-658.
3. McLean RR: Proinflammatory cytokines and osteoporosis. Curr Osteoporos
Rep 2009, 7:134-139.
4. Roux C: Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011,
22:421-433.
5. Polzer K, Diarra D, Zwerina J, Schett G: Inflammation and destruction of
the joints–the Wnt pathway. Joint Bone Spine 2008, 75:105-107.
6. Rabelo F de S, da Mota LMH, Lima RAC, Lima FAC, Barra GB, de Carvalho JF,
Amato AA: The Wnt signaling pathway and rheumatoid arthritis.
Autoimmun Rev 2010, 9:207-210.
7. Nakamura Y, Nawata M, Wakitani S: Expression profiles and functional
analyses of Wnt-related genes in human joint disorders. Am J Pathol
2005, 167:97-105.
8. Sen M, Chamorro M, Reifert J, Corr M, Carson DA: Blockade of Wnt-5A/
frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis
Rheum 2001, 44:772-781.
9. Sen M, Reifert J, Lauterbach K, Wolf V, Rubin JS, Corr M, Carson DA:
Regulation of fibronectin and metalloproteinase expression by Wnt
signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 2002,
46:2867-2877.
10. Tanaka I, Morikawa M, Okuse T, Shirakawa M, Imai K: Expression and
regulation of WISP2 in rheumatoid arthritic synovium. Biochem Biophys
Res Commun 2005, 334:973-978.
11. Garnero P, Tabassi NC-B, Voorzanger-Rousselot N: Circulating dickkopf-1
and radiological progression in patients with early rheumatoid arthritis
treated with etanercept. J Rheumatol 2008, 35:2313-2315.
12. Wang S-Y, Liu Y-Y, Ye H, Guo J-P, Li R, Liu X, Li Z-G: Circulating Dickkopf-1
is correlated with bone erosion and inflammation in rheumatoid
arthritis. J Rheumatol 2011, 38:821-827.
13. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F,
Li X, Ominsky M, Richards W, Schett G, Zwerina J: Neutralisation of Dkk-1
protects from systemic bone loss during inflammation and reduces
sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159.
14. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB,
Gravallese EM: Osteoblast function is compromised at sites of focal bone
erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572-1585.
15. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A,
Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R,
Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint
remodeling. Nat Med 2007, 13:156-163.
16. Paszty C, Turner CH, Robinson MK: Sclerostin: a gem from the genome
leads to bone-building antibodies. J Bone Miner Res 2010, 25:1897-1904.
17. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D,
Robinson MK: A short treatment with an antibody to sclerostin can
inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009,
24:1662-1671.
18. Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U: Rodent
preclinical models for developing novel antiarthritic molecules:
comparative biology and preferred methods for evaluating efficacy.
J Biomed Biotechnol 2011, 2011:569068.
19. Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL: Utility of animal
models for identification of potential therapeutics for rheumatoid
arthritis. Ann Rheum Dis 2008, 67:1505-1515.
20. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immunisation
against heterologous type II collagen induces arthritis in mice. Nature
1980, 283:666-668.
21. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A,
Robinson MK: Sclerostin antibody treatment enhances bone strength but
does not prevent growth retardation in young mice treated with
dexamethasone. Arthritis Rheum 2011, 63:2385-2395.
22. Stok KS, Noël D, Apparailly F, Gould D, Chernajovsky Y, Jorgensen C,
Müller R: Quantitative imaging of cartilage and bone for functional
assessment of gene therapy approaches in experimental arthritis.
J Tissue Eng Regen Med 2010, 4:387-394.
23. Confavreux CB, Chapurlat RD: Systemic bone effects of biologic therapies
in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011,
22:1023-1036.
24. Roudier M, Li X, Niu Q-T, Pacheco E, Pretorius J, Graham K, Yoon B-RP,
Gong J, Warmington K, Ke HZ, Black RA, Hulme J, Babij P: Sclerostin is
expressed in articular cartilage but loss or inhibition does not affect
cartilage remodeling during aging or following mechanical injury.
Arthritis Rheum 2012, 65:721-31.
Marenzana et al. Arthritis Research & Therapy 2013, 15:R125
http://arthritis-research.com/content/15/5/R125
Page 11 of 12
25. Chen X-X, Baum W, Dwyer D, Stock M, Schwabe K, Ke H-Z, Stolina M,
Schett G, Bozec A: Sclerostin inhibition reverses systemic, periarticular
and local bone loss in arthritis. Ann Rheum Dis 2013.
26. Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D,
Berthelot J-M: A combination of methotrexate and zoledronic acid
prevents bone erosions and systemic bone mass loss in collagen
induced arthritis. Arthritis Res Ther 2009, 11:R185.
27. Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D,
Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P: RANKL inhibition
by osteoprotegerin prevents bone loss without affecting local or
systemic inflammation parameters in two rat arthritis models:
comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther
2009, 11:R187.
28. Neumann T, Oelzner P, Petrow PK, Thoss K, Hein G, Stein G, Bräuer R:
Osteoprotegerin reduces the loss of periarticular bone mass in primary
and secondary spongiosa but does not influence inflammation in rat
antigen-induced arthritis. Inflamm Res 2006, 55:32-39.
29. Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA,
Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S,
Manoukian R, Manuokian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ,
Senaldi G: CD4+CD45RBHi T cell transfer induced colitis in mice is
accompanied by osteopenia which is treatable with recombinant
human osteoprotegerin. Gut 2005, 54:78-86.
doi:10.1186/ar4305
Cite this article as: Marenzana et al.: Effect of sclerostin-neutralising
antibody on periarticular and systemic bone in a murine model of
rheumatoid arthritis: a microCT study. Arthritis Research & Therapy 2013
15:R125.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Marenzana et al. Arthritis Research & Therapy 2013, 15:R125
http://arthritis-research.com/content/15/5/R125
Page 12 of 12
